Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.49 Insider Own0.50% Shs Outstand36.35M Perf Week0.93%
Market Cap1.02B Forward P/E- EPS next Y-2.84 Insider Trans-11.63% Shs Float32.33M Perf Month-27.13%
Income-78.80M PEG- EPS next Q-0.62 Inst Own77.10% Short Float4.73% Perf Quarter-17.57%
Sales11.40M P/S89.60 EPS this Y-2.40% Inst Trans-1.14% Short Ratio5.37 Perf Half Y-12.76%
Book/sh6.03 P/B4.66 EPS next Y-16.40% ROA-36.30% Target Price50.22 Perf Year196.73%
Cash/sh7.13 P/C3.94 EPS next 5Y- ROE-72.10% 52W Range11.55 - 43.23 Perf YTD43.44%
Dividend- P/FCF- EPS past 5Y-27.90% ROI-66.10% 52W High-38.21% Beta0.57
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low131.26% ATR2.17
Employees202 Current Ratio8.40 Sales Q/Q-36.70% Oper. Margin- RSI (14)30.62 Volatility6.88% 7.39%
OptionableYes Debt/Eq0.10 EPS Q/Q31.60% Profit Margin- Rel Volume1.09 Prev Close28.10
ShortableYes LT Debt/Eq0.06 EarningsNov 07 BMO Payout- Avg Volume284.87K Price26.71
Recom1.70 SMA20-17.09% SMA50-26.79% SMA200-12.41% Volume177,123 Change-4.95%
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
May-16-18Initiated Wells Fargo Outperform $47
May-07-18Reiterated Leerink Partners Outperform $26 → $63
Jan-04-18Initiated Janney Buy $25
Dec-01-17Initiated H.C. Wainwright Buy $28
Nov-07-17Initiated Evercore ISI Outperform $22
Oct-20-17Reiterated Leerink Partners Outperform $17 → $19
Dec-06-16Reiterated WallachBeth Buy $27 → $15
Nov-22-16Downgrade Jefferies Buy → Hold
Nov-16-16Downgrade Piper Jaffray Overweight → Neutral
Aug-04-16Resumed H.C. Wainwright Buy $21
Jun-15-16Reiterated WallachBeth Buy $60 → $35
Feb-24-16Resumed H.C. Wainwright Buy $30
Dec-01-15Reiterated WallachBeth Buy $33 → $60
Nov-30-15Resumed ROTH Capital Buy $37
Oct-01-15Reiterated Chardan Capital Markets Buy $35 → $40
Sep-21-15Reiterated Oppenheimer Outperform $47 → $50
Aug-28-15Reiterated WallachBeth Buy $35 → $33
Aug-27-15Reiterated Chardan Capital Markets Buy $40 → $35
Oct-18-18 06:55AM  uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies GlobeNewswire
Oct-17-18 07:00AM  uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting GlobeNewswire
Oct-16-18 07:00AM  uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Sep-28-18 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Sep-24-18 07:00AM  uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Sep-13-18 08:50AM  Implied Volatility Surging for uniQure (QURE) Stock Options Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Aug-30-18 07:00AM  uniQure to Participate at Multiple Upcoming Conferences GlobeNewswire
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-23-18 07:00AM  uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Aug-21-18 08:30AM  Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-08-18 08:40AM  UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:34AM  UniQure: 2Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jun-28-18 03:18PM  3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy Benzinga +13.58%
07:00AM  uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jun-25-18 08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-13-18 07:00AM  uniQure Announces New Appointments to its Board of Directors GlobeNewswire
Jun-06-18 08:30AM  Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-29-18 07:00AM  uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy GlobeNewswire
May-22-18 07:25AM  Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago ACCESSWIRE
May-21-18 07:00AM  uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies GlobeNewswire
May-20-18 04:38PM  Uniqure Notches Bullish Initiation On Gene Therapy Prospects Benzinga
May-18-18 07:00AM  uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy GlobeNewswire
May-14-18 07:00AM  3 Cutting-Edge Biotech Stocks That Can Double in Value TheStreet.com
May-09-18 03:05PM  3 High-Growth Stocks That Could Soar Motley Fool +5.27%
May-07-18 11:47AM  uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares GlobeNewswire
May-04-18 08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-02-18 07:32PM  uniQure Announces Pricing of its Public Offering GlobeNewswire
May-01-18 04:04PM  uniQure Announces Proposed Public Offering GlobeNewswire
Apr-30-18 12:00PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire
07:30AM  UniQure: 1Q Earnings Snapshot Associated Press
07:05AM  uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Apr-27-18 11:10AM  Kensho's genetic engineering index CNBC Videos
07:00AM  uniQure Announces to Present at Multiple Conferences in May GlobeNewswire
Apr-25-18 04:15PM  uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntingtons Disease at the 2018 American Academy of Neurology Annual Meeting GlobeNewswire
Apr-24-18 10:49AM  Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure Benzinga -7.37%
Apr-13-18 10:06AM  Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus Zacks
07:51AM  How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years? Simply Wall St.
Apr-09-18 07:35AM  Report: Developing Opportunities within Consol Energy, 51job, MakeMyTrip, LyondellBasell Industries N.V, Golden Ocean Group, and uniQure N.V Future Expectations, Projections Moving into 2018 GlobeNewswire +16.44%
Mar-20-18 11:39AM  Janney: Buy The Dip In Uniqure Benzinga +6.64%
Mar-16-18 08:25AM  Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-14-18 07:00AM  uniQure Announces 2017 Financial Results and Recent Company Progress GlobeNewswire -10.95%
Feb-27-18 07:00AM  uniQure to Participate in Multiple Conferences in March GlobeNewswire
Feb-01-18 07:00AM  uniQure to Participate in Multiple Conferences in February GlobeNewswire
Jan-22-18 07:00AM  uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntingtons disease GlobeNewswire +9.56%
Jan-08-18 07:00AM  uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value GlobeNewswire -6.93%
Dec-18-17 07:00AM  uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Dec-11-17 04:01PM  uniQure Added to NASDAQ Biotechnology Index GlobeNewswire
07:41AM  UniQure shares jump 3.8% premarket on positive trial of hemophelia treatment MarketWatch
07:00AM  uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Dec-09-17 09:00AM  uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-07-17 08:07AM  uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-01-17 09:10AM  uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
07:17AM  UniQure reports 3Q loss Associated Press
07:00AM  uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress GlobeNewswire
Oct-31-17 04:02PM  uniQure Announces Multiple Company Presentations at Upcoming November Conferences GlobeNewswire
Oct-27-17 04:03PM  uniQure Announces Closing of its Public Offering GlobeNewswire
Oct-24-17 08:14PM  uniQure Announces Pricing of its Public Offering GlobeNewswire
Oct-23-17 04:06PM  uniQure Announces Proposed Public Offering GlobeNewswire
Oct-21-17 10:32AM  3 Healthcare Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-20-17 03:00PM  Why uniQure N.V. Stock Is Hopping Today Motley Fool +27.11%
Oct-19-17 03:28PM  Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 SmarterAnalyst +60.08%
12:54PM  Why UniQure (QURE) Stock is Skyrocketing Today Zacks
07:05AM  uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua) GlobeNewswire
07:00AM  uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 GlobeNewswire
Oct-18-17 07:00AM  uniQure Presents New Preclinical Data on AMT-130 in Huntingtons Disease at the ESGCT 25th Anniversary Congress in Berlin GlobeNewswire -18.85%
Oct-17-17 08:39AM  uniQure (QURE) in Focus: Stock Moves 11.9% Higher Zacks
Oct-06-17 07:00AM  uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntingtons disease GlobeNewswire
Oct-02-17 07:00AM  uniQure Announces Company Presentations at Upcoming October Conferences GlobeNewswire +8.23%
Sep-21-17 09:34PM  Should You Buy uniQure NV (QURE)? Simply Wall St. +12.01%
Sep-20-17 12:48PM  uniQure NV :QURE-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
Aug-24-17 07:00AM  uniQure Announces Company Participation at Citi Healthcare Conference GlobeNewswire
Aug-08-17 05:22PM  UniQure reports 2Q loss Associated Press
07:00AM  uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress GlobeNewswire
Aug-07-17 07:00AM  uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors GlobeNewswire
Jul-31-17 07:00AM  uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B GlobeNewswire
Jul-21-17 07:00AM  uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program GlobeNewswire
Jul-20-17 08:20AM  uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher Zacks +6.15%
Jul-18-17 07:00AM  uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing GlobeNewswire +10.34%
Jul-11-17 06:30AM  uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies GlobeNewswire
Jul-10-17 12:46PM  uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Jul-07-17 05:08PM  A Barrage Of Biotech Updates Expected At ISTH Meeting Benzinga
Jun-23-17 07:00AM  uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress GlobeNewswire
Jun-15-17 07:00AM  uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies GlobeNewswire
Jun-06-17 07:00AM  uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer GlobeNewswire
Jun-02-17 10:20AM  uniQure NV :QURE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 07:00AM  uniQure Announces Company Presentation at Jefferies Healthcare Conference GlobeNewswire
May-11-17 07:00AM  uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates GlobeNewswire
May-10-17 07:00AM  uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates GlobeNewswire
May-09-17 07:00AM  uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress GlobeNewswire
May-01-17 07:00AM  uniQure Announces Company Presentations at Upcoming May Conferences GlobeNewswire
Apr-26-17 07:00AM  uniQure Presents New Preclinical Data on AMT-130 in Huntingtons Disease at CHDIs 12th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire +5.74%
Apr-25-17 07:05AM  uniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B GlobeNewswire
Apr-24-17 04:05PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire -6.81%
Apr-20-17 11:05AM  Biotech firm pulls pioneering gene therapy due to no demand Reuters
07:00AM  uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe GlobeNewswire
Apr-04-17 07:42AM  uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System GlobeNewswire
07:42AM  uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zelenkofske StevenChief Medical OfficerJun 06Sale37.1423,929888,723159,458Jun 08 08:58 AM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 15Sale21.7239,169850,751439,764Mar 19 03:35 PM
Soteropoulos PaulaDirectorJan 29Sale18.532,87853,32917,914Jan 31 10:51 AM
van Deventer SanderChief Scientific OfficerJan 29Sale18.535,985110,90225,069Jan 31 10:42 AM
Astley-Sparke PhilipDirectorJan 29Sale18.536,540121,18628,252Jan 31 10:39 AM
Kaye JackDirectorJan 29Sale18.532,87853,32912,914Jan 31 10:34 AM
SCHAFFER DAVIDDirectorJan 29Sale18.532,87853,32915,314Jan 31 10:30 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 04Sale19.8721,690431,069447,559Jan 05 04:40 PM
Garen JonathanChief Business OfficerJan 03Sale20.135,864118,02885,251Jan 03 05:52 PM
Firuta Paul EChief Commercial OfficerJan 03Sale20.135,864118,02885,251Jan 03 05:50 PM
Cantor Maria ESVP, Investor Relations & CommJan 03Sale20.135,864118,02885,251Jan 03 05:49 PM
KLEMT CHRISTIANChief Accounting OfficerJan 03Sale20.135,093102,51037,257Jan 05 04:41 PM